These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23892326)

  • 1. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
    Ruutu T; Gratwohl A; de Witte T; Afanasyev B; Apperley J; Bacigalupo A; Dazzi F; Dreger P; Duarte R; Finke J; Garderet L; Greinix H; Holler E; Kröger N; Lawitschka A; Mohty M; Nagler A; Passweg J; Ringdén O; Socié G; Sierra J; Sureda A; Wiktor-Jedrzejczak W; Madrigal A; Niederwieser D
    Bone Marrow Transplant; 2014 Feb; 49(2):168-73. PubMed ID: 23892326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.
    Ruutu T; van Biezen A; Hertenstein B; Henseler A; Garderet L; Passweg J; Mohty M; Sureda A; Niederwieser D; Gratwohl A; de Witte T
    Bone Marrow Transplant; 2012 Nov; 47(11):1459-64. PubMed ID: 22410750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
    Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socié G; Solano C; Vrhovac R; Zeiser R; Kröger N; Basak GW
    Lancet Haematol; 2020 Feb; 7(2):e157-e167. PubMed ID: 32004485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.
    Ruutu T; Gratwohl A; Niederwieser D; de Witte T; van der Werf S; van Biezen A; Mohty M; Kröger N; Rambaldi A; McGrath E; Sureda A; Basak G; Greinix H; Duarte RF
    Bone Marrow Transplant; 2017 Mar; 52(3):357-362. PubMed ID: 27892949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children. European Group for Blood and Marrow Transplantation (EBMT) Working Party Paediatric Diseases and the International Study Committee of the BFM family-subcommittee Bone Marrow Transplantation (IBFM-STG).
    Peters C; Minkov M; Gadner H; Klingebiel T; Niethammer D
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S57-60. PubMed ID: 9630328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
    Kröger NM; Deeg JH; Olavarria E; Niederwieser D; Bacigalupo A; Barbui T; Rambaldi A; Mesa R; Tefferi A; Griesshammer M; Gupta V; Harrison C; Alchalby H; Vannucchi AM; Cervantes F; Robin M; Ditschkowski M; Fauble V; McLornan D; Ballen K; Popat UR; Passamonti F; Rondelli D; Barosi G
    Leukemia; 2015 Nov; 29(11):2126-33. PubMed ID: 26293647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.
    Ruutu T; Niederwieser D; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1997 Apr; 19(8):759-64. PubMed ID: 9134165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
    Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
    J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
    Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
    Shaughnessy PJ; Bolwell BJ; van Besien K; Mistrik M; Grigg A; Dodds A; Prince HM; Durrant S; Ilhan O; Parenti D; Gallo J; Foss F; Apperley J; Zhang MJ; Horowitz MM; Abhyankar S
    Bone Marrow Transplant; 2010 Jun; 45(6):1068-76. PubMed ID: 19915634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations.
    Lawitschka A; Lucchini G; Strahm B; Dalle JH; Balduzzi A; Gibson B; Diaz De Heredia C; Wachowiak J; Dalissier A; Vettenranta K; Yaniv I; Bordon V; Bauer D; Bader P; Meisel R; Peters C; Corbacioglu S;
    Transpl Int; 2020 Jul; 33(7):762-772. PubMed ID: 32133691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience.
    Abdelbary H; Magdy R; Moussa M; Abdelmoaty I
    J Egypt Natl Canc Inst; 2020 Feb; 32(1):11. PubMed ID: 32372257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.